Pipeline

NPI-001

Retinitis Pigmentosa in Usher disease

A Phase 1 Clinical Trial of Nacuity’s GMP-grade NPI-001 solution in healthy volunteers was completed with acceptable results.

A randomized, placebo-controlled, double-masked, multicenter, Phase 1/2 Clinical Trial of Nacuity’s proprietary NPI-001 tablets, the SLO-RP Study, is ongoing in patients with RP associated with Usher syndrome (NCT04355689).